Differenzialdiagnosen der Parkinson-Krankheit: aktuelle Konsensuskriterien und Ausblicke

Zusammenfassung

Parkinson-Syndrome, klinisch definiert durch eine Kombination von Kardinalsymptomen, können die klinische Manifestation von unterschiedlichen, neuropathologisch definierten Krankheitsentitäten sein. Infolge der unterschiedlichen prognostischen, therapeutischen und wissenschaftlichen Implikationen ist eine sichere differenzialdiagnostische Abgrenzung der unterschiedlichen Entitäten im frühen Krankheitsverlauf erstrebenswert. Zu diesem Zweck sind standardisierte klinische diagnostische Kriterien mit ausreichender Validierung gegen den Goldstandard der neuropathologischen Diagnostik wichtig. Hier sollen die aktuell zur Verfügung stehenden klinischen diagnostischen Kriterien der atypischen Parkinson-Syndrome und deren Validität beleuchtet werden.

Abstract

Parkinsonian-syndrome, clinically based on the combination of cardinal symptoms, could be the clinical manifestation of different, neuropathological defined entities. Because of the different prognostic, therapeutical and scientific implications a reliable differential diagnostic of the entities in early course of disease is desirable. For this purpose standardized clinical diagnostic criteria with sufficient validation against the gold standard of the neuropathological diagnostic are important. In this article, the clinical diagnostic criteria of atypical Parkinsonian-syndrome and their validity were discussed.

progressive supranukleäre Blickparese - kortikobasale Degeneration - Multisystematrophie - Demenz mit Lewy-Körperchen

progressive supranuclear palsy - corticobasal degeneration - multiple system atrophy - dementia with Lewy bodies

Literatur

• 1 Schrag A. et al . Prevalence of progressive supranuclear palsy and multiple system atrophy: a cross-sectional study.  Lancet. 1999;  354 (9192) 1771-1775
• 2 Nath U. et al . The prevalence of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) in the UK.  Brain. 2001;  124 (7) 1438-1449
• 3 Stanford P M. et al . Progressive supranuclear palsy pathology caused by a novel silent mutation in exon 10 of the tau gene: expansion of the disease phenotype caused by tau gene mutations.  Brain. 2000;  123 880-893
• 4 Baker M. et al . Association of an extended haplotype in the tau gene with progressive supranuclear palsy.  Hum Mol Genet. 1999;  8 711-715
• 5 Steele S C. et al . Progressive supranuclear palsy. A heterogeneous degeneration involving the brain stem, basal ganglia and cerebellum with vertical supranuclear gaze and pseudobulbar palsy, nuchal dystonia and dementia.  Arch Neurol. 1964;  10 333-359
• 6 Litvan I. et al . Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop.  Neurology. 1996;  47 1-9
• 7 Williams D R, Lees A J. Progressive supranuclear palsy: clinicopathological concepts and diagnostic challenges.  Lancet Neurol. 2009;  8 270-279
• 8 Williams D R. et al . Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson’s syndrome and PSP-parkinsonism.  Brain. 2005;  128 1247-1258
• 9 Williams D R. et al . Pure akinesia with gait freezing: a third clinical phenotype of progressive supranuclear palsy.  Mov Disord. 2007;  22 2235-2241
• 10 Osaki Y, Ben-Shlomo Y, Lees A J. et al . Accuracy of clinical diagnosis of progressive supranuclear palsy.  Mov Disord. 2004;  19 181-189
• 11 Burn D , Lees A J. Progressive supranuclear palsy: where are we now?.  Lancet Neurol. 2002;  1 359-369
• 12 Schrag A, Ben Shlomo Y, Quinn N P. Cross sectional prevalence survey of idiopathic Parkinson’s disease and Parkinsonism in London.  BMJ. 2000;  321 21-22
• 13 Hughes A J, Daniel S E, Ben Shlomo Y. et al . The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service.  Brain. 2002;  125 861-870
• 14 Wenning G K, Colosimo C, Geser F. et al . Multiple system atrophy.  Lancet Neurol. 2004;  3 93-103
• 15 Dickson D W, Bergeron C, Chin S S. et al . Office of Rare Diseases neuropathologic criteria for corticobasal degeneration.  J Neuropathol Exp Neurol. 2002;  61 935-946
• 16 Pittman A M, Myers A J, Abou-Sleiman P. et al . Linkage disequilibrium fine mapping and haplotype association analysis of the tau gene in progressive supranuclear palsy and corticobasal degeneration.  J Med Genet. 2005;  42 837-846
• 17 Kompoliti K, Goetz C G, Boeve B F. et al . Clinical presentation and pharmacological therapy in corticobasal degeneration.  Arch Neurol. 1998;  55 957-961
• 18 Vanek Z, Jankovic J. Dystonia in corticobasal degeneration.  Mov Disord. 2001;  16 252-257
• 19 Rinne J O, Lee M S, Thompson P D. et al . Corticobasal degeneration. A clinical study of 36 cases.  Brain. 1994;  117 1183-1196
• 20 Riley D E, Lang A E, Lewis A. et al . Cortical-basal ganglionic degeneration.  Neurology. 1990;  40 1203-1212
• 21 Lang A E, Riley D E, Bergeron C. Cortical-basal ganglionic degeneration. Calne DB Neurodegenerative diseases Philadelphia; WB Saunders 1994: 877-894
• 22 Boeve B F, Lang A E, Litvan I. Corticobasal degeneration and its relationship to progressive supranuclear palsy and frontotemporal dementia.  Ann Neurol. 2003;  54 15-19
• 23 Litvan. et al . Clinical features differentiating patients with postmortem confirmed progressive supranuclear palsy and corticobasal degeneration.  J Neurol. 1999;  246 1-5
• 24 Boeve B F, Maraganore D M, Parisi J E. et al . Pathologic heterogeneity in clinically diagnosed corticobasal degeneration.  Neurology. 1999;  53 795-800
• 25 Grimes D A, Lang A E, Bergeron C B. Dementia as the most common presentation of cortico-basal ganglionic degeneration.  Neurology. 1999;  53 1969-1974
• 26 Kertesz A, Martinez-Lage P, Davidson W. et al . The corticobasal degeneration syndrome overlaps progressive aphasia and frontotemporal dementia.  Neurology. 2000;  55 1368-1375
• 27 Gilman S, Low P A, Quinn N. et al . Consensus statement on the diagnosis of multiple system atrophy.  J Neurol Sci. 1999;  163 94-98
• 28 Gilman S, Wenning G K, Low P A. et al . Second consensus statement on the diagnosis of multiple system atrophy.  Neurology. 2008;  71 670-676
• 29 Osaki Y, Ben-Shlomo Y, Lees A J. et al . A Validation Exercise on the New Consensus Criteria for Multiple System Atrophy.  Movement Disorders. in press; 
• 30 Brooks D, Seppi K. et al . Proposed Neuroimaging Criteria for the Diagnosis of Multiple System Atrophy.  Movement Disorders. 2009;  24 949-964
• 31 McKeith I G, Mintzer J, Aarsland D. et al . Review: Dementia with Lewy bodies.  Lancet Neurol. 2004;  3 19-28
• 32 Geser F, Wenning G K, Poewe W. et al . How to Diagnose Dementia With Lewy Bodies: State of the Art.  Movement Disorders. 2005;  20 11-20
• 33 Ransmayr G, Wenning G K, Seppi K. et al . Demenz mit Lewy-Körperchen.  Der Nervenarzt. 2000;  71 929-935
• 34 Zaccai J, McCracken C, Brayne C. A systematic review of prevalence and incidence studies of dementia with Lewy bodies.  Age and Ageing. 2005;  34 561-566
• 35 Rahkonen T. Dementia with Lewy bodies according to the consensus criteria in a general population aged 75 years or older.  J Neurol Neurosurg Psychiatry. 2003;  74 720-724
• 36 Stevens T, Livingston G, Kitchen G. et al . Islington study of dementia subtypes in the community.  Br J Psychiatry. 2002;  180 270-276
• 37 Ballard C, O’Brien J, Morris C M. et al . The progression of cognitive impairment in dementia with Lewy bodies, vascular dementia and Alzheimer’s disease.  Int J Geriatr Psychiatry. 2001;  16 499-503
• 38 McKeith I G, Galasko D, Kosaka K. et al . Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop.  Neurology. 1996;  47 1113-1124
• 39 McKeith I G, Perry E K, Perry R H. et al . Report of the second dementia with Lewy body international workshop: Diagnosis and treatment.  Neurology. 1999;  53 902
• 40 Hohl U, Tiraboschi P, Hansen L A. et al . Diagnostic accuracy of dementia with Lewy bodies.  Arch Neurol. 2000;  57 347-351
• 41 Lopez O L, Becker J T, Kaufer D I. et al . Research evaluation and prospective diagnosis of dementia with Lewy bodies.  Arch Neurol. 2002;  59 43-46
• 42 McKeith I G, Ballard C G, Perry R H. et al . Prospective validation of consensus criteria for the diagnosis of dementia with Lewy bodies.  Neurology. 2000;  54 1050-1058
• 43 Litvan I, MacIntyre A, Goetz C G. et al . Accuracy of the clinical diagnoses of Lewy body disease, Parkinson disease, and dementia with Lewy bodies: a clinicopathologic study.  Arch Neurol. 1998;  55 969-978
• 44 Lopez O L, Litvan I, Catt K E. et al . Accuracy of four clinical diagnostic criteria for the diagnosis of neurodegenerative dementias.  Neurology. 1999;  53 1292-1299
• 45 Luis C A, Barker W W, Gajaraj K. et al . Sensitivity and specificity of three clinical criteria for dementia with Lewy bodies in an autopsy-verified sample.  Int J Geriatr Psychiatry. 1999;  14 526-533
• 46 Mega M S, Masterman D L, Benson D F. et al . Dementia with Lewy bodies: reliability and validity of clinical and pathologic criteria.  Neurology. 1996;  47 1403-1409
• 47 Verghese J, Crystal H A, Dickson D W. et al . Validity of clinical criteria for the diagnosis of dementia with Lewy bodies.  Neurology. 1999;  53 1974-1982
• 48 McKeith I G, Dickson D W, Lowe J. et al . Diagnosis and management of dementia with Lewy bodies: Third report of the DLB consortium.  Neurology. 2005;  65 1863-1872